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Abstract In Europe and the United States, there is an
increasing prevalence of the use of autologous blood
products to facilitate healing in a variety of applications.
Recently, we have learned more about speciﬁc growth
factors, which play a crucial role in the healing process.
With that knowledge there is abundant enthusiasm in the
application of concentrated platelets, which release a
supra-maximal quantity of these growth factors to stimu-
late recovery in non-healing injuries. For 20 years, the
application of autologous PRP has been safely used and
documented in many ﬁelds including; orthopedics, sports
medicine, dentistry, ENT, neurosurgery, ophthalmology,
urology, wound healing, cosmetic, cardiothoracic, and
maxillofacial surgery. This article introduces the reader to
PRP therapy and reviews the current literature on this
emerging treatment modality. In summary, PRP provides a
promising alternative to surgery by promoting safe and
natural healing. However, there are few controlled trials,
and mostly anecdotal or case reports. Additionally the
sample sizes are frequently small, limiting the generaliza-
tion of the ﬁndings. Recently, there is emerging literature
on the beneﬁcial effects of PRP for chronic non-healing
tendon injuries including lateral epicondylitis and plantar
fasciitis and cartilage degeneration (Mishra and Pavelko,
The American Journal of Sports Medicine 10(10):1–5,
2006; Barrett and Erredge, Podiatry Today 17:37–42,
2004). However, as clinical use increases, more controlled
studies are needed to further understand this treatment.
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Introduction
In Europe, and more recently in the United States, an
increased trend has emerged in the use of autologous blood
products in an effort to facilitate healing in a variety of
applications. In recent years, scientiﬁc research and tech-
nologyhasprovideda new perspective on understandingthe
woundhealingprocess.Initiallyplateletswerethoughttoact
exclusively with clotting. However, we have learned that
plateletsalsoreleasemanybioactiveproteinsresponsiblefor
attracting macrophages, mesenchymal stem cells, and oste-
oblasts which not only promotes removal of necrotic tissue,
but also enhances tissue regeneration and healing.
Based on this principle platelets are introduced to stim-
ulate a supra-physiologic release of growth factors in an
attempt to jump start healing in chronic injuries. The current
literaturereveals a paucity of randomized clinical trials. The
existing literature is ﬁlled with mostly anecdotal reports or
case series,which typically have small sample sizes and few
control groups [1, 2]. A large multi-center trial is currently
underway providing a more objective understanding of
Platelet Rich Plasma (PRP) use in chronic epicondylitis.
According to the World Health Organization (WHO),
musculoskeletal injuries are the most common cause of
severe long-term pain and physical disability, and affect
hundreds of millions of people around the world [3]. In
fact, the years 2000–2010 have been termed ‘‘the decade of
bone and joint’’ as a global initiative to promote further
research on prevention, diagnosis, and treatment [3, 4].
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DOI 10.1007/s12178-008-9032-5Soft tissue injuries including tendon and ligament trauma
represent 45% of all musculoskeletal injuries in the USA
[4, 5]. The continued popularity of sporting activities has
brought with it an epidemic of musculoskeletal disorders
focusing attention on tendons. Additionally, modern
imaging techniques including magnetic resonance imaging
and musculoskeletal ultrasound have provided clinicians
with further knowledge of these injuries.
Blood components
Blood contains plasma, red blood cells (RBC), white blood
cells (WBC), and platelets. Plasma is the liquid component
of blood, made mostly of water and acts as a transporter for
cells. Plasma also contains ﬁbrinogen, a protein that acts
like a net and catches platelets at a wound site to form a
clot. RBC helps pick up oxygen from the lungs and delivers
it to other body cells, while removing carbon dioxide.
WBC ﬁghts infection, kills germs, and carries off dead
blood cells. Platelets are responsible for hemostasis, con-
struction of new connective tissue, and revascularization.
Typically a blood specimen contains 93% RBC, 6%
Platelets, and 1% WBC [6]. The rationale for PRP beneﬁt
lies in reversing the blood ratio by decreasing RBC to 5%,
which are less useful in the healing process, and increasing
platelets to 94% to stimulate recovery [6].
Platelets
Platelets are small discoid blood cells made in bone marrow
with a lifespan of 7–10 days. Inside the platelets are many
intracellular structures containing glycogen, lysosomes, and
twotypesofgranules.Thealphagranulescontaintheclotting
andgrowthfactorsthatareeventuallyreleasedinthehealing
process. Normally at the resting state, platelets require a
triggertoactivateandbecomeaparticipantinwoundhealing
and hemostasis [7]. Upon activation by thrombin, the
platelets morph into different shapes and develop branches,
called pseudo-pods that spread over injured tissue. This
process is termed aggregation. Eventually the granules
contained within platelets release the growth factors, which
stimulate the inﬂammatory cascade and healing [7].
PRP
Platelet Rich Plasma is deﬁned as a volume of the plasma
fraction of autologous blood having a platelet concentra-
tion above baseline [8, 9]. Normal platelet concentration is
200,000 platelets/ul. Studies have shown that clinical efﬁ-
cacy can be expected with a minimum increase of 49 this
baseline (1million platelets/ul) [6]. Slight variability exists
in the ability to concentrate platelets, largely depending on
the manufacturer’s equipment. However, it has not been
studied if too great an increased platelet concentration
would have paradoxical effects.
The use of autologous PRP was ﬁrst used in 1987 by
Ferrari et al. [10] following an open heart surgery, to avoid
excessive transfusion of homologous blood products. Since
that time, the application of autologous PRP has been
safely used and documented in many ﬁelds including;
orthopedics, sports medicine, dentistry, ENT, neurosur-
gery, ophthalmology, urology, and wound healing; as well
as cosmetic, cardiothoracic, and maxillofacial surgery.
Studies suggest that PRP can affect inﬂammation, post-
operative blood loss, infection, narcotic requirements,
osteogenesis, wound, and soft tissue healing.
In addition to local hemostasis at sites of vascular injury,
platelets contain an abundance of growth factors and
cytokines that are pivotal in soft tissue healing and bone
mineralization [4]. An increased awareness of platelets and
their role in the healing process has lead to the concept of
therapeutic applications.
Tendons
PRP is increasingly used in treatment of chronic non-heal-
ing tendon injuries including the elbow, patella, and the
achilles among others. As a result of mechanical factors,
tendons are vulnerable to injury and stubborn to heal.
Tendons are made of specialized cells including tenocytes,
water, and ﬁbrous collagen proteins. Millions of these col-
lagen proteins weave together to form a durable strand of
ﬂexible tissue to make up a tendon. They naturally anchor to
the bone and form a resilient mineralized connection.
Tendons also bear the responsibility of transferring a great
deal of force, and as a result are susceptible to injury when
they are overwhelmed. With repetitive overuse, collagen
ﬁbers in the tendon may form micro tears, leading to what is
called tendonitis; or more appropriately tendinosis or ten-
dinopathy. The injured tendons heal by scarring which
adversely affects function and increases risk of re-injury.
Furthermore, tendons heal at a slow rate compared with
other connective tissues, secondary to poor vascularization
[11–13]. Histologic samples from chronic cases indicate
that there is not an inﬂammatory response, but rather a
limitation of the normal tendon repair system with a ﬁbro-
blastic and a vascular response called, angioﬁbroblastic
degeneration [1, 14, 15]. Given the inherent nature of the
tendon, new treatment options including dry needling,
prolotherapy, and extracorporeal shockwave therapy are
aimed at embracing inﬂammation rather than suppressing it.
Traditional therapies to treat these conditions do not alter
the tendon’s inherent poor healing properties and involve
long-term palliative care [16, 17]. A recent meta-analysis of
23 randomized controlled studies on physical therapy
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cient supportive evidence of improved outcomes [1, 18].
Corticosteroids are commonly injected, however studies
suggest adverse side effects including atrophy and perma-
nent adverse structural changes in the tendon [14].
Medications including NSAIDs, while commonly used for
tendinopathies, carry signiﬁcant long-term risks including
bleedingulcers and kidneydamage. Thus, organically based
strategiestopromotehealing whilefacilitatingthereleaseof
one’s own natural growth factors is attracting interest.
Growth factors
It is widely accepted that growth factors play a central role
in the healing process and tissue regeneration [4, 19]. This
conclusion has lead to signiﬁcant research efforts exam-
ining varying growth factors and their role in repair of
tissues [4, 20]. However, there are conﬂicting reports in the
literature regarding potential beneﬁts. Although some
authors have reported improved bone formation and tissue
healing with PRP, others have had less success [4, 21, 22].
These varying results are likely attributed to the need for
additional standardized PRP protocols, preparations, and
techniques. There are a variety of commercially FDA
approved kits available with variable platelet concentra-
tions, clot activators, and leukocyte counts which could
theoretically affect the data.
Alpha granules are storage units within platelets, which
contain pre-packaged growth factors in an inactive form
(Fig. 1). The main growth factors contained in these
granules are transforming growth factor beta (TGFbeta),
vascular endothelial growth factor (VEGF) platelet-derived
growth factor (PDGF), and epithelial growth factor (EGF)
(Table 1). The granules also contain vitronectin, a cell
adhesion molecule which helps with osseointegration and
osseoconduction.
Fig. 1 Inactive platelets
Table 1 Growth factor chart
[Printed with permission from:
Eppley BL, Woodell JE,
Higgins J. Platelet quantiﬁcation
and growth factor analysis from
platelet-rich plasma:
implications for wound healing.
Plast Reconstr Surg. 2004
November;114(6):1502–8]
Platelet-derived growth factor (PDGF) Stimulates cell replication
Promotes angiogenesis
Promotes epithelialization
Promotes granulation tissue formation
Transforming growth factor (TGF) Promotes formation of extracellular matrix
Regulates bone cell metabolism
Vascular endothelial growth factor (VEGF)r Promotes angiogenesis
Epidermal growth factor (EGF) Promotes cell differentiation and stimulates
re-epithelialisation, angiogenesis and collagenase
activity
Fibroblast growth factor (FGF) Promotes proliferation of endothelial cells and ﬁbroblasts
Stimulates angiogenesis
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the regulation of cellular migration and proliferation;
stimulate cell replication, and ﬁbronectin binding interac-
tions [23] (Fig. 2). VEGF is produced at its highest levels
only after the inﬂammatory phase, and is a potent stimu-
lator of angiogenesis. Anitua et al. showed that in vitro
VEGF and Hepatocyte Growth Factor (HGF) considerably
increased following exposure to the pool of released
growth factors; suggesting they accelerate tendon cell
proliferation and stimulate type I collagen synthesis [11].
PDGF is produced following tendon damage and helps
stimulate the production of other growth factors and has
roles in tissue remodeling. PDGF promotes mesenchymal
stem cell replication, osteoid production, endothelial cell
replication, and collagen synthesis. It is likely the ﬁrst
growth factor present in a wound and starts connective
tissue healing by promoting collagen and protein synthesis
[7]. However, a recent animal study by Ranly et al. sug-
gests that PDGF may actually inhibit bone growth [24].
In vitro and in vivo studies have shown that bFGF is
both a powerful stimulator of angiogenesis and a regulator
of cellular migration and proliferation [23]. IGF-I is highly
expressed during the early inﬂammatory phase in a number
of animal tendon healing models, and likely assists in the
proliferation and migration of ﬁbroblasts and to increase
collagen production [23]. However, a laboratory analysis of
human PRP samples demonstrated increased concentra-
tions of PDGF, TGFbeta, VEGF, and EGF, while not
showing an increase in IGF-1 [25]. EGF effects are limited
to basal cells of skin and mucous membrane while inducing
cell migration and replication.
PRP preparation
Various blood separation devices have differing prepara-
tion steps essentially accomplishing similar goals. The
Biomet Biologics GPS III system is described here for
simplicity. About 30–60 ml of venous blood is drawn with
aseptic technique from the anticubital vein. An 18 or 19 g
butterﬂy needle is advised, in efforts of avoiding irritation
and trauma to the platelets which are in a resting state. The
blood is then placed in an FDA approved device and
centrifuged for 15 min at 3,200 rpm (Fig. 3). Afterward,
the blood is separated into platelet poor plasma (PPP),
RBC, and PRP. Next the PPP is extracted through a special
port and discarded from the device (Fig. 4). While the PRP
is in a vacuumed space, the device is shaken for 30 s to re-
suspend the platelets. Afterwards the PRP is withdrawn
(Fig. 5). Depending on the initial blood draw, there is
approximately 3 or 6 cc of PRP available.
Injection procedure
The area of injury is marked while taking into account the
clinical exam, and data from imaging studies such as MRI
Fig. 2 Active platelets
Fig. 3 GPS III system and centrifuge
Fig. 4 GPS III system, withdrawing of platelet poor plasma to be
discarded
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culoskeletal ultrasound with a transducer of 6–13 Hz in an
effort to more accurately localize the PRP injection. Under
sterile conditions, the patient receives a PRP injection with
or without approximately 1 cc of 1% lidocaine and 1 cc of
0.25 Marcaine directly into the area of injury. Calcium
chloride and thrombin may be added to provide a gel
matrix for the PRP to adhere to, potentially maximizing the
beneﬁt in the case of a joint space. We recommend using a
peppering technique spreading in a clock-like manner to
achieve a more expansive zone of delivery. The patient is
observed in a supine position for 15–20 min afterwards,
and is then discharged home. Patients typically experience
minimal to moderate discomfort following the injection
which may last for up to 1 week. They are instructed to ice
the injected area if needed for pain control in addition to
elevation of the limb and modiﬁcation of activity as tol-
erated. We recommend acetaminophen as the optimal
analgesic, or Vicodin for break through pain, and dissuade
the use of NSAID’s in the early post-injection period
(Fig. 6).
Safety
Any concerns of immunogenic reactions or disease transfer
are eliminated because PRP is prepared from autologous
blood. No studies have documented that PRP promotes
hyperplasia, carcinogenesis, or tumor growth. Growth
factors act on cell membranes rather than on the cell
nucleus and activate normal gene expression [7]. Growth
Factors are not mutagenic and naturally act through gene
regulation and normal wound healing feed-back control
mechanisms [6]. Relative contraindications include the
presence of a tumor, metastatic disease, active infections,
or platelet count\10 5/ul Hgb\10 g/dl. Pregnancy or
active breastfeeding are contraindications. Patients with an
allergy to Bupivicaine (Marcaine) should not receive a
local anesthetic with these substances.
The patients should be informed of the possibility of
temporary worsening symptoms after the injection. This is
likely due to the stimulation of the body’s natural response
to inﬂammatory mediators. Although adverse effects are
uncommon, as with any injection there is a possibility of
infection, no relief of symptoms, and neurovascular injury.
Scar tissue formation and calciﬁcation at the injection site
are also remote risks.
An allergic reaction or local toxicity to Bupivacaine
HCL or Lidocaine, although uncommon could trigger an
adverse reaction. Additionally, when used in surgical
applications for grafting or with intra-articular injections,
PRP may be combined with calcium chloride and bovine
thrombin to form a gel matrix. This bovine thrombin which
is used to activate PRP, in the past has been associated with
life threatening coagulopathies as a result of antibodies to
clotting factors V, XI, and thrombin [7, 26]. However,
since 1997 production has eliminated contamination of
bovine thrombin with bovine factor Va. Prior to 1997, Va
levels were 50 mg/ml and now are \0.2 mg/ml with no
further reports of complications [6].
Literature review
There isextensivedocumentation ofbothanimalandhuman
studies, with widespread applications, demonstrating the
Fig. 5 GPS III withdrawing of platelet rich plasma for injection/graft
Fig. 6 Musculoskeletal ultrasound, common extensor tendinosis
Curr Rev Musculoskelet Med (2008) 1:165–174 169safety and efﬁcacy of PRP for 20 years. However, most
studies are pilot studies with small sample sizes. Recently,
there is emerging literature on the beneﬁcial effects of PRP
for chronic non-healing tendon injuries including lateral
epicondylitis and plantar fasciitis [1, 2]. Other orthopedic
applicationsincludediabeticwoundmanagement,treatment
ofnon-unions,and usein acutetendon injuries. There isalso
a range of publications in other ﬁelds including ENT, car-
diology, and plastic surgery. The following is a review of
some of the more recent studies on PRP.
Elbow
In a recent study in the American Journal of Sports Med-
icine, Mishra et al. evaluated 140 patients with chronic
epicondylar elbow pain. Of those patients, 20 met the study
criteria and were surgical candidates who had failed con-
servative treatments. In total, 15 were treated with one PRP
injection and ﬁve were controls with local anesthetic. The
treatment group noted 60% improvement at 8 weeks, 81%
at 6 months, and 93% at ﬁnal follow-up at 12–38 months.
Of note, there were no adverse effects or complications.
Additionally, there was a 94% return to sporting activities
and a 99% return to daily activities [1]. The major limi-
tation of this study was the 60% attrition rate in the control
group as 3/5 of the patients withdrew from the study or
sought outside treatment at 8 weeks. This small retro-
spective series is considered a pilot study and a randomized
clinical trial is needed to substantiate these ﬁndings.
In 2003 Edwards and Calandruccio, demonstrated that
22 of 28 patients (79%) with refractory chronic epicon-
dylitis were completely pain free following autologous
blood injection therapy [15]. There was no reported
worsening or recurrence of pain and no other adverse
events. Pain after autologous blood administration was
variable, but most patients reported it to be similar to prior
steroid injections they received before the study. One
patient failed to improve satisfactorily and eventually
underwent surgery [15]. This study is limited by its small
sample size and lack of control group.
Foot and ankle
Barett et al. enrolled nine patients in a pilot study to
evaluate PRP injections with plantar fasciitis. Patients met
the criteria if they were willing to avoid conservative
treatments including bracing, NSAIDS, and avoidance of a
cortisone injection for 90 days prior. All patients demon-
strated hypoechoic and thickened plantar fascia on
ultrasound. While anesthetizing each patient with a block
of the posterior tibial and sural nerve, 3 cc of autolo-
gous PRP was injected under ultrasound guidance (Fig. 7).
Post-injection thickness and increased signal intensity of
the fascial bands were seen on ultrasound. Six of nine
patients achieved complete symptomatic relief after
2 months. One of the three unsuccessful patients eventually
found complete relief following an additional PRP injec-
tion. At one year 77.9% patients had complete resolution of
symptoms [2]. Again, this was a non-controlled pilot study
with a small sample size.
Knee
After injecting rat patellar tendons with PRP, Kajikawa
et al. showed increased quantity of circulation-derived
cells in the early phase of tendon repair after injury versus
controls. Unfortunately, these helpful cells normally dis-
appear with time; therefore prolonging their presence is
beneﬁcial. Furthermore, they showed increased type I & III
collagen and macrophages [27].
Taylor, et al. demonstrated safety and efﬁcacy while
injecting autologous blood into New Zealand white rabbits
at the patellar tendon. After reviewing the histology at 6
and 12 weeks, there was no adverse change in histology or
tendon stiffness. However, the tendons injected with blood
were signiﬁcantly stronger [28].
Berghoff et al. retrospectively reviewed a large series of
patients in an effort to access autologous blood product
effects in patients undergoing total knee arthroplasty
(TKA). The study included 66 control patients and 71
patients treated with autologous blood products at the
wound site. The intervention group demonstrated higher
hemoglobin levels and fewer transfusions as well as shorter
hospitalization and greater knee range of motion at
6 weeks. Additionally, no infections occurred and signiﬁ-
cantly fewer narcotics were required [29]. Although limited
by the retrospective nature of the study, the results are
compelling.
Fig. 7 Ultrasound guided suprapatella bursa injection/graft
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a series of patients undergoing TKA. The patients were
treated with an intra-operative platelet gel; resulting in
lower blood loss, improved early range of motion, and
fewer narcotic requirements [30].
In a controlled study by Everts et al., of 160 patients
undergoing Total Knee Replacements (TKA) 85 received
Platelet gel and ﬁbrin sealants; which resulted in decreased
blood transfusion requirements, lower post-surgical wound
disturbances, shorter hospital stay, and fewer infections
[31].
Wounds
Non-healing cutaneous wounds represent a challenging
problem and are commonly related to peripheral vascular
disease, infection, trauma, neurologic and immunologic
conditions, as well as neoplastic and metabolic disorders.
These chronic ulcerative wounds represent signiﬁcant
impact both psychologically and socioeconomically. An
analysis of the surfaces of chronic pressure wounds
(decubitus ulcers) revealed a decreased growth factor
concentration compared with an acute wound [32]. In a
study by Crovetti et al., 24 patients with chronic cutane-
ous ulcers were treated with a series of PRP Gel
treatments. Only three patients received autologous blood
PRP due to medical issues, while the others received
donor blood product. Nine patients demonstrated com-
plete wound healing. Of those nine, one wound reopened
at 4 months. There were two reports of wound infection,
both with positive Staph Aureus which were successfully
treated with oral antibiotics. There were no adverse
effects encountered and all patients noted decreased pain
[32].
Another wound study by McAleer et al., involved 24
patients with 33 chronic non-healing lower extremity
wounds. Patients failed conservative treatment for
[6 months with a lack of reduction of surface area. Sur-
gical wound debridement was initially performed to
convert chronic ulcers to acute wounds, in an effort to
promote wound metabolism and chemotaxis. The wounds
were injected with PRP every 2 weeks. Successful wound
closure and epitheliazation was obtained in 20 wounds. The
mean time for closure was 11.15 weeks. Five wounds
displayed no improvement [33]. These ﬁndings were par-
ticularly signiﬁcant because all patients had failed
previously available treatment methods.
Bone
Diabetes impairs fracture healing with reduced early pro-
liferation of cells, delayed osteogenesis, and diminished
biomechanical properties of the fracture callus [34, 35]. In
an animal study by Gandhi et al., male Wister rats received
closed mid-diaphyseal fractures after 14 days of the onset
of diabetes. PRP did not alter blood glucose levels or
HbA1c. The study demonstrated that diabetic rats had
decreased growth factors compared to non-diabetic group
[34].
Not all studies on autologous growth factors have shown
favorable results with promoting bone formation and
healing. In a recent study by Ranly et al., PRP was shown
to decrease osteoinductivity of demineralized bone matrix
in immunocompromised mice. PRP from six healthy men
was implanted as gelatin capsules in the calves of inbred
nude mice. After 56 days the mice were killed and the
studied calf muscles suggest that PDGF may actually
reduce osteoinductivity [24]. The main criticism of this
study is related to the PRP treatment protocol. Conven-
tional PRP processing kits yield a 6-fold increase in platelet
concentration. However, in the Ranly study the PRP con-
centration was only four times above baseline.
Additionally, the timing of the assays looking at osteoin-
duction may have been too late to accurately access early
bone formation.
Spine
Generally, maintaining arthrodesis in a posterolateral
lumbar fusion can be challenging and may necessitate
revision [36]. Subsequently multiple strategies have
evolved to decrease non-union rates including screw
instrumentation, interbody fusion, bone morphogenic pro-
tein, and limiting risk factors such as smoking, NSAID, and
corticosteroid use [37]. There is mixed literature and con-
troversy surrounding the efﬁcacy of platelet gel to
supplement autologous bone graft during instrumented
posterolateral spinal fusion [37–39]. The potential efﬁcacy
of PRP to facilitate osteoinduction in spine fusion remains
uncertain at present time.
A study by Carreon et al. investigated 76 patients with
posterior lateral lumbar fusion with autologous iliac crest
bone graft mixed with PRP compared to a control group.
Using 500 ml of whole blood, 30 ml of platelet concentrate
was obtained. Non-union was diagnosed by either a revi-
sion intra-operatively or via plain radiographs or CT scan.
The study concluded that the PRP group had a 25% non-
union rate versus 17% in the control group at a minimal
2-year follow-up [37]. Of note, platelet concentrations
were not measured before or after preparation, as this is not
routinely performed clinically.
A study of single-level intertransverse fusions by Wei-
ner and Walker demonstrated a 62% fusion rate in iliac
graft augmented with PRP versus 91% fusion rate in bone
graft alone [40].
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patients with PRP after 13 months. There was no pseudo-
arthrosis seen on exploration or plain radiographs in 100%
of cases [41].
Hee et al. examined 23 patients who underwent instru-
mented transforaminal lumbar interbody fusions with PRP
versus control with a 2-year follow-up. Interestingly they
found accelerated bony healing in the PRP group; however
it did not result in increased fusion rates versus control
[36]. Platelet concentrations were measured after prepara-
tion and were increased 489% from baseline [36].
Jenis et al. explored anterior interbody lumbar fusions in
22 patients with autograph using iliac crest bone graft
versus 15 patients with allograft combined with PRP. CT
scans at 6 months and plain radiographs at 12 and
24 months demonstrated an 85% fusion rate for autograft
versus 89% with PRP and allograft [38]. This could
potentially eradicate the morbidity from iliac crest har-
vesting, and provide a more cost effective alternative to
costly bone induction techniques.
A study from Chen et al. demonstrated that PRP might
potentially play a role in prevention of disc degeneration.
They demonstrated that PRP can act as a growth factor
cocktail to induce proliferation and differentiation and
promote tissue-engineered nucleus formation regeneration
via the Smad pathway [42]. This offers a conservative
management option to patients with degenerative disc
disease, besides traditional management options including
cortosteroid injection and ultimately surgery.
Summary
In summary, for over 20 years PRP has been used safely in
a variety of conditions with promising implications.
Unfortunately, most studies to date are anecdotal or involve
small sample sizes. Undoubtedly we are seeing increased
clinical use of PRP, however more clinical trials are cer-
tainly needed. Little is documented in the literature
regarding the expected timeframe of tendon healing post-
PRP injection. Also, there are no studies to date that review
the need of post-PRP injection rehabilitation, nor are there
any protocols. However, it is assumed that Physical/
Occupational therapy and restoring the kinetic chain will
help facilitate recovery post injection.
The authors are currently expanding PRP injection
applications from tendon injuries to other persistent ail-
ments including greater trochanteric bursitis and knee
osteoarthritis with favorable results. The authors also have
had success in injecting professional soccer athletes with
acute MCL knee injuries in an effort to accelerate their
return to play (Fig. 8). Further understanding of this
promising treatment is required to determine which
particular diagnoses are amenable to PRP therapy. The
authors will report results on this topic in the near future.
The use of autologous growth factors in the form of PRP
may be just the beginning of a new medical frontier known
as ‘‘orthobiologics.’’ First generation injectables such as
visco-supplementation have been successful in the treat-
ment of pain for patients with osteoarthritis of the knee.
These injections represent a non-biologic effort to inﬂu-
ence the biochemical environment of the joint.
A second generation of injectables is now available
with PRP. This technology provides delivery of a highly
concentrated potent cocktail of growth factors to stimu-
late healing. TGF-b, contained in PRP has been linked to
chondrogenesis in cartilage repair [43]. New reports
presented at the 2007 International Cartilage Repair
Society Meeting in Warsaw indicate PRP enhancement
of chondrocyte cell proliferation and positive clinical
effects on degenerative knee cartilage [44, 45]. Anitua
and Sanchez recently demonstrated increased hyluronic
acid concentration balancing angiogenesis in ten osteo-
arthritic knee patients [46]. Wu et al. documented PRP
promotion of chondrogenesis as an injectable scaffold
while seeded with chondrocytes in rabbit ears. Hard
knobbles were found and seen on MRI, as well as his-
tologic analysis and staining which conﬁrmed cartilage
growth [47].
Future generations of biologic injectables may target
speciﬁc cells, rather than providing an assortment of non-
speciﬁc healing properties. Currently clinical trials of
intra-articular use of growth factor BMP 7 (OPI) are
underway. Soft tissue applications of BMP7 (OPI) are also
in its early stages. Bone marrow aspirate stem cell injec-
tions are seeing increased clinical use as well. Ultimately,
stem cell therapy represents the greatest biologic healing
potential.
Fig. 8 Ultrasound guided knee MCL injection/graft
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